Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

By C. Fuchs, T. Doi, R. Jang, K. Muro, T. Satoh, M. Machado, Weijing Sun, S. Jalal, M. Shah, J. Metges and 19 more. JAMA Oncology, 2018

1,609 citations recorded by the source corpus.

Subfields: Accounting, Political Science and International Relations

View Paper: https://www.semanticscholar.org/paper/87cf4eb14cfc38890443faa7bd41029a14c8179e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Zeng
2. Timothy A. Chan
3. C. Luchini
4. F. Bibeau
5. M. Ligtenberg
6. Naveena Singh
7. A. Nottegar
8. E. Jaffee

Citations in the corpus

• Gastric cancer: a comprehensive review of current and future treatment strategies (2020, result): “Although the Epstein-Barr virus is found to be the cause of disease in a small percentage of gastric cancer patients worldwide, it was found that this disease has better survival outcomes compared with Epstein-Barr negative patients and these patients may further benefit from immunotherapy and have ”
• Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures (2019, background): “However, these responses occur only in a minority of patients, and several studies have found that PD-1 expression, PD-L1 expression, MSI status, and mutation load are not efficient biomarkers for predicting the benefits of immune-checkpoint blockade (15, 69, 70).”
• Gastric cancer treatment: recent progress and future perspectives (2023, methodology): “KEYNOTE-059 was a phase II study that explored the effect of pembrolizumab in patients with advanced GC after progression from ≥ 2 lines of treatment [63].”
• ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. (2019, methodology): “For example, the panel with dinucleotides is being used in the ongoing phase II trials NCT03435107 and NCT03150706 (https://www.clinicaltrials. gov, last accessed 28 September 2018), whereas the panel with five poly-A repeats has been used in published trials Keynote-016 and Keynote-059 [7, 43].”
• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “PD-L1 expression by IHC is an FDA-approved companion diagnostic test for pembrolizumab in NSCLC, gastric / gastroesophageal junction adenocarcinoma, cervical cancer and UC [15-20], and has shown some predictive ability across several other cancer types including head and neck and small cell lung car”